FMT
Amritsar, India
FMT
Amritsar, India

Time filter

Source Type

Microbiome leader Prof. Borody at China FMT Conference calls for Investment in Faecal Transplant Clinical Trials to Fight Serious Diseases A future where faecal transplants in China will cure conditions like autism, IBD, arthritis, Parkinson's disease and even MS was presented by global Faecal Microbiota Transplantation (FMT) leader Professor Thomas Borody (MD, PhD) at the opening of the China Microbiota Transplantation Conference in Nanjing, in his keynote presentation on non Clostridium difficile conditions (April 12-14, 2017). Professor Borody, the founder and Medical Director of the Centre for Digestive Diseases (CDD) in Sydney, Australia said many diseases have a unique microbiome profile which can be progressively changed to a normal profile with FMT treatment (www.cdd.com.au). The conference, hosted by the Chinese Medical Doctor Association, attracted more than 700 attendees with 50 oral presentations from China, Australia, USA and Europe. FMT has its origins in China with earliest treatments dating back to the 4th century. Prof. Borody is at the forefront of FMT research being first to report successful treatment of IBD in 1988. He invented, among other therapies, the freeze-dried oral FMT capsule system. He is also globally recognized as the first physician to successfully formulate the highly effective Triple Therapy that become the gold standard for treating Helicobacter pylori infection, which can lead to peptic ulcers and stomach cancer, so common in China. Prof. Borody in his presentation also shared findings from recent ground-breaking clinical trials in IBD and autism that he personally designed and was involved as an example of the need for greater FMT clinical trial investment in serious diseases: -- The FOCUS Study -- the first adequately powered randomized double blind controlled trial for ulcerative colitis -- The Autism Study -- where cognitive improvement change was found after just 5 weeks of treatment At the CDD, Prof. Borody has had success using FMT in a broad range of conditions including IBS, IBD, autism and other neurological and autoimmune diseases. He said more research funding was needed to bring FMT treatment into the mainstream medical world. "We've seen profound remission in three MS patients that are out of wheelchairs," he said. Like the US and Australia China is facing increasing challenges around the management of diseases, many with rising incidence including IBD, Parkinson's disease, MS, and many autoimmune conditions. At the state-of-the-art CDD facility in Sydney Prof. Borody and his team have performed more than 12,000 FMTs. "The healthy human flora or its components, appears to be the most complete probiotic treatment available today, capable of eradicating 'bad' bacteria and spores and supplying 'good' bacteria for recolonization of the damaged gut microbiome," said Prof. Borody. Prior to the conference Prof. Borody visited the FMT Bank in Nanjing with China's FMT leader Professor Faming Zhang, who was the first to perform FMT in China and has carried out over 1600 treatments to date. Prof. Borody has collaborated closely with Professor Faming Zhang, the Director of Intestinal Diseases Center at the 2nd Affiliated Hospital, Nanjing Medical University. About: What is Faecal Microbiota Transplantation The human bowel contains a complex population of bacteria known as the gut microbiota. These organisms and the chemicals they produce can affect the bowel and the body as a whole, and these effects can have both positive and negative impacts on a person's health. The human gut microbiota protects us from pathogenic or 'bad' bacteria. FMT involves the infusion of healthy human donor faecal bacteria via colonoscope or enema into a bowel that contains abnormal bacteria that are making the bowel 'sick'. This infusion process can be a single infusion or it can be repeated over a period of time, depending on the severity of the patient's condition. The use of healthy human flora appears to be the most complete probiotic treatment available today, capable of eradicating 'bad' bacteria and spores and supplying 'good' bacteria for recolonisation of the gut in certain conditions. The Centre for Digestive Diseases offers FMT primarily for the treatment of Clostridium difficile and treats selected patients with ulcerative colitis, irritable bowel sydrome, constipation and Crohn's disease. Other conditions are assessed on a case by case basis. About: Prof. Thomas Borody BSc (MED) (HONS), MBBS (HONS), MD, PhD, DSc, FRACP, FACG, FACP, AGAF Medical Director, Gastroenterologist (www.cdd.com.au) Prof. Thomas Borody is the founder and Medical Director of CDD. His keen interest in medical research led to the establishment of the Centre to provide both diagnostic procedures and effective treatments. Prof. Borody has published over 250 articles and abstracts. His knowledge and expertise has been sought after by patients from around the world. He is a reviewer for numerous medical journals and has developed novel therapies in gastrointestinal areas such as Inflammatory Bowel Disease, Irritable Bowel Syndrome, Parasite infestation, ulcer disease and resistant Helicobacter pylori and C. difficile. Prof. Borody continues to conduct research in order to improve current therapies and develop new treatments. Contact: Susan Fitzpatrick-Napier Digital Mantra Group SG +65 6809 3869 AU +61 2 8218 2144 USA +1 650 798 5238 Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS


Microbiome leader Prof. Borody at China FMT Conference calls for Investment in Faecal Transplant Clinical Trials to Fight Serious Diseases A future where faecal transplants in China will cure conditions like autism, IBD, arthritis, Parkinson's disease and even MS was presented by global Faecal Microbiota Transplantation (FMT) leader Professor Thomas Borody (MD, PhD) in his keynote presentation on non Clostridium difficile conditions, to open the international China Microbiota Transplantation Conference in Nanjing (April 12-14, 2017). Professor Borody, the Founder and Medical Director of the Centre for Digestive Diseases (CDD) in Sydney, Australia said many diseases have a unique microbiome profile which can be progressively changed to a normal profile with FMT treatment. At the state-of-the-art CDD facility, Prof. Borody and his team have performed more than 12,000 FMTs. Prof. Borody is at the forefront of FMT research, being the first to report successful treatment of IBD in 1988. He invented, among other therapies, the freeze-dried oral FMT capsule system. He is also recognized as the first physician to successfully formulate the highly effective Triple Therapy that would become the gold standard for treating Helicobacter pylori infection, which can lead to peptic ulcers and stomach cancer, so common in China. In his keynote presentation, Prof. Borody also shared findings from recent ground-breaking clinical trials in IBD and autism, which he personally designed and remained involved in, as examples of the need for greater FMT clinical trial investment in serious diseases: -- The FOCUS Study - the first adequately powered randomized double blind controlled trial for ulcerative colitis -- The Autism Study - where cognitive improvement change was found after just 5 weeks of treatment He said more research funding was needed to bring FMT treatment into the mainstream medical world. "The healthy human flora or its components, appears to be the most complete probiotic treatment available today, capable of eradicating 'bad' bacteria and spores and supplying 'good' bacteria for recolonization of the damaged gut microbiome," said Prof. Borody. Prior to the conference Prof. Borody visited the FMT Bank in Nanjing with China's FMT leader Professor Faming Zhang, who was the first to perform FMT in China and has carried out over 1600 treatments to date. Prof. Borody has collaborated closely with Professor Faming Zhang, who is the Director of Intestinal Diseases Center at the 2nd Affiliated Hospital, Nanjing Medical University. Like the US and Australia, China is facing increasing challenges around the management of diseases, many with rising incidence including IBD, Parkinson's disease, MS, and many autoimmune conditions. About: What is Faecal Microbiota Transplantation The human bowel contains a complex population of bacteria known as the gut microbiota. These organisms and the chemicals they produce can affect the bowel and the body as a whole, and these effects can have both positive and negative impacts on a person's health. The human gut microbiota protects us from pathogenic or 'bad' bacteria. FMT involves the infusion of healthy human donor faecal bacteria via colonoscope or enema into a bowel that contains abnormal bacteria that are making the bowel 'sick'. This infusion process can be a single infusion or it can be repeated over a period of time, depending on the severity of the patient's condition. The use of healthy human flora appears to be the most complete probiotic treatment available today, capable of eradicating 'bad' bacteria and spores and supplying 'good' bacteria for recolonisation of the gut in certain conditions. The Centre for Digestive Diseases offers FMT primarily for the treatment of Clostridium difficile and treats selected patients with ulcerative colitis, irritable bowel sydrome, constipation and Crohn's disease. Other conditions are assessed on a case by case basis. About: Prof. Thomas Borody BSc (MED) (HONS), MBBS (HONS), MD, PhD, DSc, FRACP, FACG, FACP, AGAF Medical Director, Gastroenterologist (www.cdd.com.au) Prof. Thomas Borody is the founder and Medical Director of CDD. His keen interest in medical research led to the establishment of the Centre to provide both diagnostic procedures and effective treatments. Prof. Borody has published over 250 articles and abstracts. His knowledge and expertise has been sought after by patients from around the world. He is a reviewer for numerous medical journals and has developed novel therapies in gastrointestinal areas such as Inflammatory Bowel Disease, Irritable Bowel Syndrome, Parasite infestation, ulcer disease and resistant Helicobacter pylori and C. difficile. Prof. Borody continues to conduct research in order to improve current therapies and develop new treatments. Contact: Susan Fitzpatrick-Napier Digital Mantra Group SG +65 6809 3869 AU +61 2 8218 2144 USA +1 650 798 5238


Faecal Microbiota Transplantation (FMT) leader Professor Thomas Borody (MD, PhD) has called for a national faecal bank to fight drug resistant and epidemic diseases in hospitals and clinics across the country. Professor Borody, the Founder and Medical Director of the Centre for Digestive Diseases (CDD) in Sydney was the first in Australia to perform FMT, and he set up the world's first faecal bank in 1988. Since then CDD has carried out more than 12,000 FMT's and he has trained physicians from around the world in FMT techniques. Now many countries have their own national FMT banks, including several in the US and two in Asia. "It's time Australia had a national FMT Bank that rapidly provided hospitals and clinics around the country with a high quality, safe, uniform enema product for FMT treatment that will save lives," Prof. Borody said. Fewer than five hospitals in Australia carry out FMT which means thousands of people are missing out on proven FMT procedures, when at times the only alternative is radical bowel surgery. "FMT is rapidly becoming the standard practice of care for a range of drug resistant or relapsing diseases including Clostridium difficile infection and Ulcerative Colitis, and research in FMT for Irritable Bowel Syndrome (IBS) is continuing. Some of these conditions can ruin lives and may be fatal." Prof. Borody initiated a randomized clinical trial in Australia, the results published in the Lancet earlier this year, "The FOCUS study, on effectively treating Ulcerative Colitis using repeated FMT", http://bit.ly/2pY01Gn. This trial was in part funded by Prof Borody's CDD Research Fund, Broad Medical Research Program, Mount Sinai SUCCESS fund, and the National Health and Medical Research Foundation among others. Prof. Borody continued, "As more research is done on modern epidemics like Autism, Dementia, obesity, MS and Parkinson's disease, FMT is likely to play a significant role in managing and possibly even curing these conditions." Most recently Prof. Borody was involved in an Autism study in the US, in which 18 ASD-diagnosed children were treated using FMT. The Trial not only demonstrated progressive improvement in gastrointestinal symptoms commonly present in children with Autism, but also reported significant cognitive improvements beginning in some at five weeks an onwards. The Autism study was published in January of this year in Microbiome, entitled 'Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study', http://bit.ly/2pY01Gn. The Australian FMT Bank would require approximately AUD$250K to set up a simple, single unit with an ongoing maintenance fund to run the Bank. Later, a network of centres and donors to supply steady and reliable FMT material for each state would be required. Ideally it would be federally funded, as it would save the health system millions of dollars per year. However, private support is also an option said Prof. Borody, stating that he would be keen to contribute, given his experience in carrying out 12,000+ FMTs at the state-of-the-art CDD facility in Sydney since 1988. "At the CDD we already have patients coming in from around the world for FMT treatment. This is a great opportunity for Australian hospitals, with the support of a national FMT Bank, to become world-class FMT providers." About Faecal Microbiota Transplantation The human bowel contains a complex population of bacteria known as the gut microbiota. These organisms and the chemicals they produce can affect the bowel and the body as a whole, and these effects can have both positive and negative impacts on a person's health. The human gut microbiota protects us from pathogenic or 'bad' bacteria. FMT involves the infusion of healthy human donor faecal bacteria via colonoscope or enema into a bowel that contains abnormal bacteria that are making the bowel 'sick'. This infusion process can be a single infusion or it can be repeated over a period of time, depending on the severity of the patient's condition. The use of healthy human flora appears to be the most complete probiotic treatment available today, capable of eradicating 'bad' bacteria and spores and supplying 'good' bacteria for recolonisation of the gut in certain conditions. About Prof. Thomas Borody BSc (MED) (HONS), MBBS (HONS), MD, PhD, DSc, FRACP, FACG, FACP, AGAF Medical Director, Gastroenterologist, Centre for Digestive Diseases (CDD) - www.cdd.com.au. Prof. Thomas Borody is the Founder and Medical Director of CDD. His keen interest in medical research led to the establishment of the Centre to provide both diagnostic procedures and effective treatments. Prof. Borody has published over 250 articles and abstracts. His knowledge and expertise has been sought after by patients from around the world. He is a reviewer for numerous medical journals and has developed novel therapies in gastrointestinal areas such as Inflammatory Bowel Disease, Irritable Bowel Syndrome, Parasite infestation, ulcer disease and resistant Helicobacter pylori and C. difficile. Prof. Borody continues to conduct research in order to improve current therapies and develop new treatments. To learn more, please see www.cdd.com.au. Media Contact: Susan Fitzpatrick-Napier Digital Mantra Group SG +65 6809 3869 AU +61 2 8218 2144 USA +1 650 798 5238 Professor Borody, the founder and Medical Director of the Centre for Digestive Diseases (CDD) in Sydney set up the world's first faecal bank in 1988. Professor Borody, the founder and Medical Director of the Centre for Digestive Diseases (CDD) in Sydney set up the world's first faecal bank in 1988 in surgery at the CDD. Microbiome leader Prof. Borody at China FMT Conference calls for Investment in Faecal Transplant Clinical Trials to Fight Serious Diseases


News Article | May 24, 2017
Site: www.prweb.com

Altec Products, Inc., a leader in enterprise document management and workflow solutions, announced today its participation in nVerge 2017 – a one-day technology conference in San Diego, CA. At nVerge 2017, Altec will be highlighting DocLink, Altec’s document management solution, which allows users to fully utilize and enhance their Sage ERP solutions by providing improved visibility and control to the entire document lifecycle. DocLink offers a secure, single repository to store, search for, retrieve and send all documents, effectively eliminating the need to file paper documents. This is the fifth installment of the annual nVerge event and the fifth consecutive year Altec is sponsoring it. During the one-day conference, nVerge attendees can choose between 24 different educational sessions and roundtable discussions on Microsoft Dynamics 365 (CRM) & GP, NetSuite, SAP Business ByDesign, Business Intelligence Solutions, Office 365, Azure Cloud, third-party applications, IT systems and general business management best practices. Premiere local and national businesses, including Taco Bell, T-Bird Restaurant Group, Inc. and EcoArk Holdings, Inc. will share real-life stories and experiences from their respective technology implementations, their impact and outcomes. A large exhibition floor with IT service providers and independent software vendors, including Altec, offers attendees a great opportunity to discover new technologies, obtain valuable insights and network with industry experts and peers. The agenda also includes a keynote from Dr. Victoria Halsey—Vice President of Applied Learning, The Ken Blanchard Companies—on Leading People Through Change. “Our goal with nVerge 2017 is to provide an opportunity for business owners and end-users to experience the latest technology trends and solutions that can help transform their critical business processes. nVerge will highlight solutions from Microsoft, Oracle + NetSuite and SAP, as well as third-party software applications such as Altec, designed to enhance the value and functionality of the core platforms,” says Eric Casazza, CEO of FMT Consultants and adds, “Altec is one of our trusted and longstanding partners, and we’re thrilled to have them part of the nVerge 2017 conference program.” Altec president and COO Don Howren comments, “Altec is driven to ensure that our partnership with our customers and partners such as FMT Consultants is strong and seamless. Events such as nVerge 2017 are a great opportunity for Altec to share with users how DocLink’s full integration to their ERP solution creates a productive organization functioning at full capacity.” nVerge 2017 takes place on Thursday, May 25th, 7:30 AM – 4:00 PM at Marriott Del Mar in San Diego, CA. For more information and registration, visit http://www.nVerge2017.com or contact Emily Matkin at ematkin(at)fmtconsultants(dot)com or 760.930.6400. nVerge 2017 is hosted by FMT Consultants and sponsored by Solver, Paramount WorkPlace, ClickDimensions, Nodus, Binary Stream, DocuSign, Avalara, Purely Cloud, MineralTree, TitaniumGP, eOne Solutions, Altec, k-eCommerce, SalesPad and MetaViewer. FMT is a seasoned provider of integrated business solutions and information technology services throughout the US and Canada with a significant presence in San Diego County, Los Angeles County, and Orange County. Since 1995, FMT’s experienced team of experts has been partnering with clients to integrate, configure and customize innovative technology solutions to help them improve and streamline their business operations. The company has offices in Carlsbad and Los Angeles, CA. Visit http://www.fmtconsultants.com or call 760.930.6400 for more information. Altec is a leading provider of integrated document management and workflow solutions. Its flagship product, DocLink, enables companies to capture, archive, workflow, and route any document for any process, anywhere. Connecting data for thousands of customers globally, Altec also enjoys strong, collaborative partnerships with ERP solution providers such as Amtech, Epicor, Microsoft, Sage, and SAP B1 to provide the most comprehensive enterprise document management solution. Learn more at http://www.altec-inc.com.


News Article | April 25, 2017
Site: www.prweb.com

Harper and FMT to team up on integrating patented microwave technologies to enable advanced material processing furnace systems(PRWeb April 25, 2017)Read the full story at http://www.prweb.com/releases/2017/04/prweb14255142.htm


News Article | February 21, 2017
Site: www.prweb.com

Diversified Machine Systems (DMS), headquartered in Colorado, manufactures the highest quality 5 axis and 3 axis CNC machines in the industry. DMS has recently created a new design in their Freedom Machine Tool product line. This new machine, the FMT Plus, provides a greater degree of versatility without sacrificing rigidity. This FMT Plus machine offers a Z axis of up to 15 inches, an increase from its previous top-line FMT router by eight inches. This enables customers to route materials having greater levels of height and thicknesses such as plastic, dense wood and foam composites. The FMT Plus is comprised of a fully stress-relieved, laser-calibrated steel frame. The frame is then outfitted with 30mm motion rails on both the X and Y axis’s. These are driven by 30mm and 40mm ball-screw assemblies, respectively. This precision engineering ensures a durable, long-lasting, high-quality routing machine. “Designing this machine was more than simply adding more Z axis height to an existing FMT machine. To ensure we maintained the quality FMT is known for, our engineers redesigned the machine to fully-incorporate the additional Z axis height into a completely new machine," says FMT sales and marketing manager, Andrew Townsend. Freedom Machine Tool, a division of Diversified Machine Systems (DMS), is a manufacturer of affordable, 3 axis CNC routers. Freedom Machine Tool was founded to address the need in the market for a cost-effective, industrial quality CNC machining solution without sacrificing on quality or reliability. Freedom Machine Tool manufactures the Patriot 4x4 CNC Router, Patriot 4x8 CNC Router, Patriot 4x8 Lathe, Patriot 5x10 CNC Router for the woodworking industry, the Orthorout 4x4 and 4x8 for the orthotics industry and the Office Machining Center for the medical office manufacturing industry.


News Article | January 26, 2017
Site: www.techtimes.com

Fecal transplant may sound gross but according to a new study from Ohio State University, fecal transplants may actually be beneficial to children with autism. Fecal transplant, otherwise known as bacteriotherapy, is the method of introducing microbes from healthy donors into the gastrointestinal (GI) tract of people suffering from severe stomach problems, such as recurrent C. difficile colitis. Fecal transplant efficiently replenishes the good bacteria or probiotics that have been killed or suppressed, usually through the excessive use of antibiotics. In the study, the researchers used microbiota transfer therapy or fecal microbiota transplant (FMT). In FMT, fecal sample is collected from the healthy donor, mixed with a saline or other solution, filtered, and transferred to the patient via colonoscopy, endoscopy, sigmoidoscopy, or enema. "Transplants are working for people with other gastrointestinal problems. And, with autism, gastrointestinal symptoms are often severe, so we thought this could be potentially valuable," said Ann Gregory, one of the study's lead authors and a microbiology graduate student at The Ohio State University. The study, which is set to be published in the journal Microbiome, looked into 18 kids diagnosed with autism and moderate to severe GI conditions. Both doctors and parents reported that they saw positive changes in all of the participants' stomach health and behavior autism symptoms that lasted eight weeks after the fecal transplant treatment was done. Nevertheless, parents with autistic children should never attempt to do fecal transplant at home. "More research is needed before this can be used for treatment," Gregory warned. "Microbiota should be very carefully screened, and the treatment should be done under medical supervision." Gastrointestinal disorders are consistently seen among children diagnosed with autism spectrum disorder (ASD). Research shows 70 percent of the children with ASD had GI issues compared to 42 percent of the children with developmental disorder other than ASD. Autistic individuals, like everyone else, are also susceptible to gastritis, irritable bowel syndrome (IBS), and severe food allergies. The exact reason behind why GI disorders are more pervasive in children with autism is yet unknown. However, there is a push for researchers to focus their work on addressing autism during the early life of children. "Even though GI symptoms are common in early childhood, physicians should be mindful that children with ASD may be experiencing more GI difficulties in the first three years of life," autism researchers from Columbia University, wrote in the March 25 issue of the journal JAMA Psychiatry. © 2017 Tech Times, All rights reserved. Do not reproduce without permission.


SOMERVILLE, Mass.--(BUSINESS WIRE)--OpenBiome, a public stool bank, announced today that it has entered into a collaboration with Finch Therapeutics, a microbiome biopharmaceutical company, to enable FDA approval of a fecal transplant pill for the treatment of recurrent C. difficile infection. Finch will be licensing OpenBiome’s biomanufacturing quality systems and incorporating manufacturing upgrades as well as its own drug delivery technology to prepare the product for clinical trials and eventual marketing authorization. Since delivering its first treatment in October 2013, OpenBiome has distributed more than 21,000 treatments to its network of over 800 hospitals and clinics. Fecal microbiota transplantation (FMT) is used to treat C. difficile infections that are not responsive to antibiotic therapies. C. difficile is the most common hospital-acquired infection in the country, affecting 453,000 patients a year, and resulting in an estimated 29,000 deaths. 1 in 5 patients do not respond to first-line antibiotics. For patients who fail multiple courses of antibiotic treatment, fecal transplantation has been shown to prevent recurrence in more than 85% of cases. OpenBiome was founded to expand safe access to fecal transplantation for patients with recurrent C. difficile infection and to catalyze research on the role of the microbiome in human health. The stool bank provides clinicians with rigorously screened, ready-to-use stool microbiota preparations and supports researchers with a suite of tools to discover how gut bacteria might treat diseases beyond C. difficile. When it launched, patients in need of fecal transplants often had to travel significant distances for a visit to one of the few fecal transplant practitioners in the country. Today, more than 97% of the US population lives within a two-hour drive of a provider using OpenBiome material to perform FMT. An interim policy from the U.S. Food and Drug Administration (FDA) allows physicians to perform FMT for the treatment of recurrent C. difficile infection, despite the fact that the therapy is not FDA-approved. Medical professional societies and clinical researchers advocated for the policy based on the available literature on FMT’s safety and efficacy and the lack of treatment alternatives for this patient population. “To preserve patient access to this treatment option, and given the scale that we’ve reached, demonstrating the safety and efficacy of fecal transplantation through adequate and well-controlled clinical trials is the right thing to do,” explained Carolyn Edelstein, OpenBiome’s director of Outreach and Public Affairs, in an op-ed published earlier today with the Fecal Transplant Foundation. OpenBiome will continue to supply clinicians and researchers with material, manufactured by Finch, under prevailing FDA policy and in support of its nonprofit mission to enable patient access and research. Under the terms of the collaboration, OpenBiome will license its quality system for biomanufacturing to Finch. Finch will incorporate its novel drug delivery technology to enable the targeted release of microbes at the site of the C. difficile infection in the colon. Finch will also upgrade the manufacturing system to support FDA approval, and will provide material produced in this improved quality environment to OpenBiome. FIN-403 is the lead product candidate emerging from this partnership. Finch expects to begin enrolling for a Phase II clinical trial to evaluate the safety and efficacy of FIN-403 for the prevention of recurrence in recurrent C. difficile patients in the second half of 2017. OpenBiome will receive a series of upfront payments, ongoing milestone payments, and royalties on sales of FIN-403 and other products developed in the collaboration. With these resources, OpenBiome will support early-stage, high-risk, long-term microbiome research programs that might not be able to secure traditional funding. With this additional funding for its independent research program, OpenBiome will work to advance public knowledge on how gut bacteria can be engineered to help cure or even prevent disease. Dr. Mark Smith, PhD, OpenBiome’s co-founder and research director, will be stepping down from his roles at OpenBiome to serve as the CEO at Finch. He will maintain a seat on the OpenBiome Board of Directors and serve as an advisor to OpenBiome’s Scientific Review Board. “This affiliation will allow us to execute our mission at a level we could not have imagined before,” said James Burgess, OpenBiome’s Executive Director, in a letter to OpenBiome’s clinicians and researchers. “Through it, we will provide safe access to fecal transplantation for patients with recurrent C. difficile today, and help Finch pursue FDA approval so that patients have this access in perpetuity. OpenBiome will continue to catalyze research in the microbiome by providing clinical investigators with logistical and material support, and by facilitating the kind of discoveries that will help cure or even prevent disease. We are thrilled by the path ahead.” About OpenBiome OpenBiome is the first public stool bank, founded to expand safe access to fecal transplantation for patients with recurrent C. difficile infection and to catalyze research on the microbiome’s role in human health. OpenBiome provides clinicians with rigorously screened, ready-to-use stool preparations and supports researchers with a suite of tools to discover how gut bacteria might treat diseases beyond C. difficile. Since 2013, OpenBiome has partnered with over 800 healthcare institutions across all 50 states and 6 countries to deliver more than 21,000 treatments for recurrent C. difficile. Its research portfolio includes 49% of all U.S. trials exploring the use of fecal transplants in new diseases. About Finch Finch Therapeutics is a mission-driven biopharmaceutical company that aims to develop novel microbial therapies serving patients with serious and unmet medical needs. Founded by data scientists, clinicians, and microbiologists from MIT and OpenBiome, Finch uses machine-learning algorithms informed by high-throughput molecular data to reverse engineer successful experiences with fecal transplantation. Through this and other clinical datasets, Finch identifies the microbes that drive desirable patient outcomes, and develops therapies that deliver those microbial communities to the patient. As Finch’s first clinical-stage program, FIN-403 provides both a short-term opportunity for impacting C. difficile and a long-term platform for designing new therapies.


News Article | February 24, 2017
Site: www.prweb.com

FMT Consultants, a leading provider of integrated business management solutions and information technology services based in San Diego and Los Angeles, has announced that it has earned the Microsoft Silver Cloud Customer Relationship Management (CRM) Competency, bringing the firm’s total number of competencies from Microsoft to eight. Achieving the Microsoft Silver Cloud CRM Competency validates FMT as a premier provider of Microsoft Dynamics 365 (formerly Dynamics CRM Online)—Microsoft’s cloud-based customer relationship management solution. To achieve the Silver Cloud CRM Competency, FMT team members successfully completed exams and are now recognized Microsoft Certified Professionals. Additionally, FMT demonstrated its ability to deliver successful projects and assessments by exceeding several software revenue goals, and providing multiple customer references. “As a leading technology provider, we are constantly working to expand and deepen our expertise so that we can continue to help customers realize the full benefit of their solutions,” says Eric Casazza, CEO of FMT Consultants, and adds, “our goal is to make it easy for customers to migrate to the cloud and immediately see the positive impact on their business. Achieving the Microsoft Silver Cloud CRM Competency demonstrates our continued commitment and efforts to provide expert advice and excellent service to all our customers.” FMT Consultants has now achieved five Microsoft Gold Competencies: Gold Cloud Platform, Gold Cloud Productivity, Gold Content and Collaboration, Gold Customer Relationship Management, and Gold Enterprise Resource Planning. Microsoft Silver Competencies for the firm include the Silver Cloud Customer Relationship Management, Silver Midmarket Cloud Solutions, and Silver Application Development. About FMT Consultants FMT is a seasoned provider of integrated business solutions and information technology services throughout the US and Canada with a significant presence in San Diego County, Los Angeles County, and Orange County. Since 1995, FMT’s experienced team of experts has been partnering with clients to integrate, configure and customize innovative technology solutions to help them improve and streamline their business operations. The company has offices in Carlsbad and Los Angeles, CA. Visit http://www.fmtconsultants.com or call 760.930.6400 for more information.


News Article | February 15, 2017
Site: www.prweb.com

Fitness Machine Technicians, specialists in the maintenance and repair of exercise equipment for gyms, corporations, hotels, and private residences, announced that Bruce Sturgeon of Doylestown, PA and Jack Brady of New Britain, PA acquired Bucks and Lehigh county markets. A technician for over ten years, Bruce Sturgeon has worked with Fitness Machine Technicians for the past four years. Originally from Baltimore, MD, he has been involved in the fitness industry for over 20 years. “I’ve had the pleasure of getting to know Bruce over the last few years and am excited about his new venture within Fitness Machine Technicians. We are happy he has chosen to stay a part of the team,” said founder and CEO, Don Powers. After learning about the unique opportunity from Sturgeon, Jack Brady, a Temple University graduate with a degree in business and over 25 years of sales experience, was eager to join. Sturgeon said, “Because Jack and I live in the area, we know the businesses and people who reside in this great community. We are providing a unique and needed service to our area—specifically servicing fitness machines owned by our own neighbors and friends.” Colleges, homes, hotel chains and recreation and fitness centers continue to expand their facilities to accommodate the growing interest in exercise as a part of ongoing wellness. Treadmills, elliptical, stationary bikes and stair steppers must be maintained to ensure their ongoing availability to members, residents and guests. Fitness Machine Technicians offers reliable service/repair and maintenance services on a variety of exercise equipment on a contract and non-contract basis. The company currently services counties including Philadelphia, Montgomery, Chester, Berks, Camden, Gloucester, and New Castle and is looking to expand further throughout the Mid-Atlantic region. Since beginning this business concept over ten years ago, the demand for services has expanded throughout the region. For private residences or public facilities, Fitness Machine Technicians customers can request a technician by calling 844-FMT-FIXX or via http://fitnessmachinetechnicians.com/request-a-tech/. About Fitness Machine Technicians Fitness Machine Technicians specializes in the maintenance and repair of equipment for commercial and home exercise facilities. In addition to providing basic service, parts replacement and maintenance on a contract or per call basis, the company also assists in the design of facilities, recommending equipment layouts for maximum functionality. Clients include health clubs, corporations, hotels, condos, education, government and residential throughout the Mid-Atlantic region. Fitness Machine Technicians also offers franchise opportunities to individuals with an interest in fitness and looking to run a service-based business based on a proven operating model. For more information, visit the website at http://www.fitnessmachinetechnicians.com or call 844-FMT-FIXX.

Loading FMT collaborators
Loading FMT collaborators